Duvelisib is the new upcoming PI3K inhibitor and I was wondering if any of my CLL fellows had experience with the drug. I am on the CAPTIVATE trial combining Ibrutinib and Venetoclax and it seems to me that adding something like Duvelisib would go after another pathway to neutralize whatever could be left of the CLL. I am trying to assess if the drug will actually be effective as a mono therapy or only in combination.
Duvelisib or not?: Duvelisib is the new upcoming... - CLL Support
Dr. Matthew Davids has a duvelisib and venetoclax clinic trial in the wings, should open later this year. It is a safety and dosing trial primarily.
I was on idelalisib and rituxan, same pathway... I did well, friends of mine had a lot of problems... however.